Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications

Agata Bikiewicz1,2*, Maciej Banach1,2, Stephan von Haehling3, Marek Maciejewski4 and Agata Bielecka-Dabrowa1,2

1Heart Failure Unit, Department of Cardiology and Congenital Diseases of Adults, Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Rzgowska 281/289, Lodz, 93-338, Poland; 2Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland; 3Department of Cardiology and Pneumology and German Center for Cardiovascular Research (DZHK), partner site Göttingen, University Medical Center Göttingen (UMG), Göttingen, Germany; and 4Department of Cardiology and Congenital Diseases of Adults, Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

Abstract

The most common cancer diagnosis in female population is breast cancer, which affects every year about 2.0 million women worldwide. In recent years, significant progress has been made in oncological therapy, in systemic treatment, and in radiotherapy of breast cancer. Unfortunately, the improvement in the effectiveness of oncological treatment and prolonging patients’ life span is associated with more frequent occurrence of organ complications, which are side effects of this treatment. Current recommendations suggest a periodic monitoring of the cardiovascular system in course of oncological treatment. The monitoring includes the assessment of occurrence of risk factors for cardiovascular diseases in combination with the evaluation of the left ventricular systolic function using echocardiography and electrocardiography as well as with the analysis of the concentration of cardiac biomarkers. The aim of this review was critical assessment of the breast cancer therapy cardiotoxicity and the analysis of methods its detections. The new cardio-specific biomarkers in serum, the development of modern imaging techniques (Global Longitudinal Strain and Three-Dimensional Left Ventricular Ejection Fraction) and genotyping, and especially their combined use, may become a useful tool for identifying patients at risk of developing cardiotoxicity, who require further cardiovascular monitoring or cardioprotective therapy.

Keywords Cardiotoxicity; Heart failure; Breast cancer; Biomarkers; Oncological treatment

Introduction

Epidemiology breast cancer

The most common cancer diagnosis in women is breast cancer, which affects about 2.0 million women worldwide every year between 45 and 69 years of age, and about half a million die because of it.1 The most important factors increasing the risk of breast cancer include alcohol abuse, smoking (especially before the age of 44 years), genetic factors, a family history of cancer, high socioeconomic status, the use of hormone replacement therapy in postmenopausal women and also contraceptives, a history of benign breast lesions, more advanced age (over 50 years), and reproductive factors. Genetic factors particularly include gene mutations affecting BRCA1 (breast cancer susceptibility gene 1; breast cancer 1, early onset located on a long arm of chromosome 17) and BRCA2 (breast cancer susceptibility gene 2; breast cancer 2, early onset located on a long arm of chromosome 13). Reproductive factors embrace early puberty, late menopause, and late age of the first full-term pregnancy.1,2 Owing to the introduction of population screening tests in 1986 in the UK and in the USA as well as in 2003 in the European Union member countries, the detection of breast cancer at an early stage of the disease development has increased. The related mortality has decreased. Currently, mammography is a screening...
test recommended by European and American Cancer Societies; in Europe, mammography is intended for women aged 50–69 years to be performed every 2 years.¹–⁴

Search strategy

We searched the electronic database PUBMED (2000 to 2020). Additionally, abstracts from national and international cardiovascular meetings, summaries of product characteristics, and selected monographs were searched. When necessary, the relevant authors were contacted to obtain further data. The main data search terms were breast cancer, adjuvant therapy, radiotherapy, toxicity of oncological treatment, diagnosis and cardiotoxicity, biomarker(s), marker(s), microRNA, anthracycline transporter proteins, and diagnosis and heart failure.

Pathomechanism and clinical symptoms of cardiovascular damage in patients undergoing chemotherapy and radiotherapy for breast cancer

The improvement in the effectiveness of oncological treatments and the prolongation patients’ life expectancy are in some patients associated with the occurrence of organ complications as side effects of this treatment. The most common complications involve the dysfunction of the cardiovascular system manifested by damage of cardiomyocytes. Such damage can lead to asymptomatic left ventricular dysfunction or even overt heart failure, abnormal valve function, cardiac arrhythmias and conduction disorders, myocarditis, pericarditis, as well as endothelial damage and premature development of atherosclerosis and thromboembolic complications.⁵–⁹

Myocardial damage after the use of cardiotoxic drugs in women (chemotherapy-related cardiac dysfunction; CTRCD) is defined as a decrease in left ventricular ejection fraction (LVEF) of >10 percentage points, to a value <53%.¹⁰,¹¹ Among oncological drugs with proven cardiotoxic effects, there are cytostatic agents (anthracycline antibiotics, 5-fluorouracil, and cyclophosphamide), molecularly targeted drugs (trastuzumab and pertuzumab), taxanes, and radiotherapy.⁵,⁶,⁸,⁹

Anthracyclines

Anthracyclines are antibiotics produced by Streptomyces peucetius var. caesius, which are commonly used in the treatment of breast cancer.¹²,¹³ Their cardiotoxic effects are related to several mechanisms like DNA structure damage, lipid peroxidation, and changes in the structure of cell membranes¹²,¹³ as well as in the activation of p53 (tumour-suppressor protein), mitochondrial dysfunction, the generation of free oxygen radicals, and, in consequence, the death of myocardial cells.¹⁴–¹⁶

Another important mechanism for the cardiotoxicity of anthracycline drugs is associated with excessive accumulation of iron ions in cardiomyocytes and the production of free radicals.¹⁷,¹⁸

Apoptosis is another mechanisms of myocardial cell damage. Anthracyclines inhibit the phosphatidylinositol 3-kinase (PI3K/Akt) pathway,¹⁹–²² altering cell susceptibility to anthracycline-induced apoptosis (Figure 1).¹⁹–²²

Figure 1  Actions of anthracyclines in the cell. After entering the cell, anthracyclines (AC) cause mitochondrial damage and disrupt transcription in nuclear DNA.
Regardless of the mechanism, the action of anthracyclines finally causes the damage to genetic material and blocks cell proliferation, which consequently leads to the death of both cancer and myocardial cells.12–22

Anthracycline-induced cardiotoxicity can be divided into acute, early-onset chronic progressive cardiotoxicity, and late-onset chronic progressive cardiotoxicity.23–26 Acute toxicity is quite rare (<1%), and it does not depend on the dose. It occurs during the infusion of cytostatics or up to 2 weeks after its completion. The most common clinical image of acute anthracycline-induced cardiotoxicity are the supraventricular arrhythmias, symptoms suggestive of myocarditis and pericarditis, left ventricular systolic dysfunction, and changes in the electrocardiogram (non-specific ST-T segment changes and QTc interval prolongation). The acute cardiotoxicity is usually reversible, but if it is accompanied by an increase in cardiac biochemical markers, it can lead to progressive heart failure.23–25 Early-onset chronic progressive cardiotoxicity occurs in 1.6–2.1% of patients, and it often develops asymptotically within the first 12 months after the completion of treatment. Late-onset chronic progressive cardiotoxicity occurs in 1.5–5% of patients after 1 year from the initial exposure and even after 10–20 years after the completion of anthracyclines treatment.23–26 The anthracycline cardiotoxicity depends on a total cumulative dose. Currently, the maximum doxorubicin dose is 450–550 mg/m². The dose of 450 mg/m² is used in case of patients with concomitant risk factors for cardiomyopathy, while the dose of 550 mg/m² can be used in those without additional risk factors.27 The use of doxorubicin at a dose exceeding the maximum dose significantly increases the risk of myocardial damage and left ventricular dysfunction.27,28 This risk is around 5% for the 400 mg/m² dose, 26% for the 550 mg/m² dose, and over 48% for the total dose of 700 mg/m².28 Anthracycline-induced cardiotoxicity is manifested by progressive and mostly irreversible impairment of diastolic function, followed by left ventricular systolic dysfunction, accompanied by cardiac arrhythmias, low electrocardiographic QRS voltage and an increase in cardiac troponin levels.23–26 However, there is increasing evidence of myocardial recovery after anthracycline-induced damage. Cardinale et al., in the study of 201 patients with myocardial injury after anthracycline treatment (LVEF < 45%), observed normalization of the LVEF in 64% of the patients that treatment with enalapril and carvedilol within 2 months after the completion of chemotherapy.29

Targeted therapy for breast cancer

Recently, oncological treatment of breast cancer has been supplemented with targeted therapy involving drugs directed at specific molecular targets, such as membrane receptor kinases. The membrane receptor kinases are engaged in signalling pathways that are essential for the development of cancer. They include substances that act extracellularly (monoclonal antibodies) or intracellularly (tyrosine kinase inhibitors).5,8,27 Monoclonal antibodies bind to specific receptors on cell surface, thus inhibiting signalling pathways regulated by these receptors. Antibodies and small molecule inhibitors of specific HER2 receptor kinases are main compounds used in targeted therapy of breast cancer.5,8,27,28

Monoclonal antibodies

Trastuzumab—human epidermal growth factor receptor type 2 (HER2) antagonist

Trastuzumab is the representative of the first group of drugs used in the therapy of breast cancer overexpressing HER2 receptors.5,8,30 It is a humanized monoclonal antibody targeting the human epidermal growth factor HER2 receptor.5,8,30–33 Trastuzumab-related myocardial dysfunction, especially in combination with anthracyclines, is a significant limitation of oncological therapy. HER2 receptor is expressed by myocardial cells. As a result of trastuzumab activity, oxidative stress increases the concentration of angiotensin II in cardiomyocytes, which blocks the binding of neuregulin 1 to HER receptors, inhibiting anti-apoptotic cell pathways. Blocking HER2-activated cell pathways impairs growth and repair mechanisms in cardiomyocytes, which results in myocardial dysfunction.34,35 Myocardial damage is in most cases reversible. However, the evidence from retrospective studies indicates that the cardiotoxic side effects of trastuzumab may persist many years after the completion of the therapy; consequently, they are not always reversible as it was initially suggested.34,36,37 Cardiotoxicity involves structural and functional changes in contractile proteins and mitochondria and rarely leads to cell death. Moreover, it does not depend on the drug dose. It develops during treatment or in a short period after the completion of chemotherapy. The most common clinical image of anti-HER2-related cardiotoxicity is left ventricular systolic dysfunction, without any associated changes in electrocardiographic records, with rarely co-existing severe symptoms of heart failure.36–37

Therapies based on the combined administration of anthracyclines and trastuzumab improve treatment results by over 50% and increase the survival rate of patients with HER2 positive breast cancer by 35%.38–41 The effectiveness of the combined use of these drugs is unfortunately limited by an increased risk (5–10%) of myocardial dysfunction and severe heart failure.39 Cardiomyocyte damage related to anthracycline activity increases HER2 expression, which activates intracellular repair processes.39–41 Inhibition of HER2 activity by trastuzumab increases myocardial cell susceptibility to anthracycline toxicity.39–41 Myocardial injury following the combination therapy of anthracyclines and trastuzumab is usually irreversible.41
Bevacizumab—VEGF endothelial growth factor antagonist

Despite the breast cancer indication for bevacizumab had been withdrawn by FDA after concluding that the drug has not been shown to be safe and effective for the treatment of breast cancer, some experts consider it an option for extensive cutaneous inflammatory disease due to its potential antiangiogenic effect.

Tyrosine kinase inhibitors

Lapatinib is an oral, reversible inhibitor of EGFR and HER2 tyrosine kinases approved for the treatment of patients with HER2-positive metastatic breast cancer who fail to respond to anthracyclines, taxanes, and trastuzumab therapy. Cardiotoxicity induced by tyrosine kinase inhibitors develops when the target of an inhibitor is a kinase whose function is important for the proper functioning of the cardiovascular system.

Lapatinib treatment is associated with a lower risk of cardiovascular adverse reactions than trastuzumab. Lapatinib-related cardiotoxicity in the form of reversible left ventricular systolic dysfunction develops in approximately 1.5% of patients. However, it is not a reason for a permanent discontinuation of oncolgical treatment.

Alkylating agents—cyclophosphamide

Apart from anthracycline drugs, in a conventional chemotherapy for breast cancer, alkylating agents such as cyclophosphamide are also used. The pathogenesis of cyclophosphamide-related cardiotoxicity is associated with toxic effects of its active metabolites on cardiomyocytes and endothelial cells, through the production of free oxygen radicals and lipid peroxidation. In consequence, this leads to vascular endothelial damage, exudate, haemorrhage, and interstitial oedema, which clinically manifest as haemorrhagic myocarditis, myocarditis, and pericarditis with accompanying pericardial fluid and asymptomatic left ventricular dysfunction or symptomatic heart failure that is usually reversible. Moreover, changes in electrocardiographic record, including supraventricular and ventricular tachyarrhythmias, atrioventricular conduction blocks, low amplitude of QRS complexes, and changes in the ST-T segment are observed.

Symptoms of myocardial damage occur up to 10 days after drug administration, and usually, they disappear after few days. One of the most important risk factor for cyclophosphamide-induced cardiotoxicity is the use of high drug doses (Santos et al. more than 270 mg/kg over 1–4 days and Goldberg et al. doses equal or greater than 1.55 g/m²). However, acute toxicity has been reported even after total doses of 100 mg/kg. Furthermore, it seems that cyclophosphamide cardiotoxicity manifests more often in lymphoma patients than breast cancer patients. The advanced age, pre-existing heart disease, concomitant or previous use of cardiotoxic drugs, and the history of local radiation of the heart region are also associated with cyclophosphamide-related cardiotoxicity.

Antimetabolites

Antimetabolites, fluoro-derivatives of pyrimidine, such as 5-fluorouracil (5-FU) and its oral prodrug, capecitabine, are compounds that cytostatic activity is related to the inhibition of the production of nucleic acid precursors necessary for DNA replication. The pathomechanism of fluoropyrimidine-related cardiotoxicity is associated with the toxic effects of their metabolites, that is, fluoroacetate and fluoro-β-alanine, on coronary artery myocytes and direct damage to cardiomyocytes. Resting and exercise angina as well as myocardial infarction resulting from coronary vasospasm and reduced myocardial perfusion are the most common clinical images of fluoropyrimidine-related cardiotoxicity. Moreover, supraventricular and ventricular tachyarrhythmias, bradycardia, myocarditis and pericarditis, heart failure, and even deaths.

Microtubule inhibitors

Substances belonging to microtubule inhibitors used in oncotherapy of breast cancer include taxanes: paclitaxel, isolated from short-leaf yew (Taxus brevifolia) and docetaxel, isolated from English yew (Taxus baccata). Taxanes in combination with anthracyclines exert the strongest toxic effect on the heart muscle. Taxanes stimulate the transformation of an anthracycline molecule into its alcohol derivative in a NADPH reductase-dependent manner, thus resulting in the formation of doxorubicinol and epirubicinol, which impair iron and calcium homeostasis and increase the production of oxygen free radicals more intensively than doxorubicin and epirubicin. Symptoms of taxane-induced cardiotoxicity include left ventricular dysfunction, asymptomatic bradycardia, arrhythmias, and conduction disorders.

Ionizing radiation

Apart from systemic treatment, radiation therapy plays a very important role in adjuvant therapy for breast cancer. Due to the widespread use of this method of treatment, adverse effects of radiation therapy on the cardiovascular system are more often observed, even many years after irradiation. The pathomechanism of the damaging effect of radiation therapy on cardiovascular system structures involves direct ionization and damage of cell components by radiation and by water radiolysis products. The coronary and
microcirculation damage is one of radiotherapy complication. It can lead to faster development of coronary heart disease, complicated by atherosclerotic plaque rupture, thrombosis, and frequently asymptomatic myocardial infarction as a result of radiation-related nerve ending damage.87 In case of radiation due to left breast cancer, the left anterior descending artery of the left coronary artery is most often affected, and stenoses are usually located in the ostial part of the vessel.92 Significant lesions in coronary vessels occur 10–15 years after radiotherapy.93

Valve defects are another significant complication after ionizing radiation treatment for breast cancer, which occurs in about 10% of patients.90 This defect mainly affects the valves of the left part of the heart, and pathological changes include fibrosis and calcification of the aortic bulb, aortic valve leaflets, mitral ring, and a basal and a central part of the mitral valve leaflets.94–96 This most often leads to mitral and aortic valve regurgitation and also to aortic stenosis.94–96 Mean time to onset of clinical symptoms of radiation-induced valve injury is approximately 98 months.94

Heart failure is a complication, which is also observed after the use of ionizing radiation.90 Radiation induces the formation of interstitial fibrosis loci with varying diameters in the myocardium. These loci are frequently located on the anterior wall of the heart, and they rarely cover the entire muscle.90,97

It can also cause microcirculation damage by creating inflammatory infiltrates within small-sized and medium-sized arteries, fibrosis, and endothelial cell damage.88,90 HFrEF is more frequently observed in patients who received both anthracycline and radiation therapy.90

Currently, the incidence of this complication is decreasing due to the introduction of modern radiotherapy techniques based on a computerized treatment planning system (TPS).98–99 Acute radiation-induced pericarditis occurs after 2 to 145 months (mean 58 months) after radiotherapy in 2–5% of patients.100,101 Late radiation-induced pericardial disease develops between 6 months to 15 years after radiation therapy, on average, after 12 months.92,102,103 It can occur in the form of acute late pericarditis or the presence of chronic fluid in the pericardial sac, which is often asymptomatic.23 In most of cases, it resolves spontaneously; however, in up to 20% of patients, especially those who received high doses of radiation, the development of chronic and/or constrictive pericarditis has been reported.23,102 The damage to the cardiac conduction system and heart autonomic system is a very rare but equally important complication of radiation therapy. It occurs especially after the administration of high doses of radiation, including high fractional doses.23,103 The clinical picture involves mainly sinus bradycardia, conduction blocks at all levels of the conduction system, and sick sinus syndrome.23,90 Also, QTc prolongation has been observed in patients receiving combination therapy with anthracyclines. Autonomic system damage is manifested by inadequate sinus tachycardia and a lack of heart rate variability.23,91,103

Toxic effects of radiation therapy on the heart muscle are mainly determined by the dose, the location of the tumour, and the volume of the heart exposed to radiation (the risk increases significantly when the volume of the heart irradiated exceeds 50%).90

The summary of cardiotoxic symptoms related to adjuvant breast cancer treatment as well as prevention methods is presented in Table 1.

### Predictors of myocardial damage after chemotherapy and radiation therapy for breast cancer

Adjuvant therapy for breast cancer (both systemic and radiation therapy) is necessary to reduce morbidity and mortality.5,8 The cardiotoxicity of this therapy can lead to the development of heart failure and may negatively affect quality of life and prognosis.11,23,24 The high cardiotoxicity-related morbidity and mortality rates associated with antineoplastic therapy for breast cancer could be reduced with the early use of cardioprotective drugs.23,24,121–131

Therefore, it is important to assess the cardiovascular system in each patient before starting oncological therapy and to closely monitor heart muscle during and after treatment.23,24,132–133 The choice of myocardial function assessment method and the time at which it should be performed in patients with planned adjuvant treatment of breast cancer are precisely specified in the recommendations of American (ASCO, ASE, the American Society of Echocardiography) and European (ESMO, European Society for Medical Oncology; ESC, European Society of Cardiology; EACVI, the European Association of Cardiovascular Imaging) experts in oncology and cardiology.11,23,24,133 Echocardiography is the first-line diagnostic tool for the assessment of the cardiovascular system in patients undergoing therapy for breast cancer, which is recommended by the aforementioned experts.11,23,24,133 The ESC, ESMO, and ASE/EACVI guidelines also recommend the measurement of cardiac biomarkers together with echocardiography after each chemotherapy cycle (ESC/ESMO)23,24 or during follow-up echocardiography (ASE/EACVI).11

The most important current recommendations are summarized in Table 2.

### Most important current recommendations are summarized in Table 2

The detection of myocardial damage at the subclinical stage enables early initiation of cardioprotective therapy and prevents the development of irreversible heart failure.23,24,133 Diagnostic methods, both imaging and biochemical, which are recommended and currently used in monitoring of patients with breast cancer who receive potentially cardiotoxic chemotherapy, are an important tool in the prevention of heart failure.11,23,24,133–135 However, the low sensitivity of left ventricular ejection fraction

---

ESC Heart Failure (2021) DOI: 10.1002/ehf2.13365
assessment limits its use in preventive strategy. New parameters, such as biomarkers and new imaging parameters, might be used in the early detection of myocardial dysfunction.

**Imaging tests**

**Echocardiography**

Besides electrocardiography (including measurement of heart rate QTc), also echocardiography is the primary diagnostic test for chemotherapy-related myocardial damage (CTRCD). It is the most commonly used tool for the assessment of cardiac function before the qualification for chemotherapy, as well as during treatment, due to its widespread availability, low cost, and safety. According to the ASE/EACVI consensus, the decrease of LVEF by 10% to a value below 53% is considered as the evidence of an existing CTRCD.

Left ventricular ejection fraction (LVEF), estimated using the 2D biplane Simpson’s method or more precisely, with the use of three-dimensional (3D) technique, is the basic parameter assessed during this examination. Decrease in left ventricular ejection fraction is a late, often irreversible sign of toxic damage to myocardium. The assessment of global longitudinal strain (GLS) is a sensitive echocardiographic method for the detection of early myocardial damage. Myocardial deformation is measured using tissue Doppler mode or the speckle tracking echocardiography (STE). They evaluate both segmental and generalized disorders of systolic and diastolic functions of myocardium.

### Table 1  Cardiotoxicity of adjuvant breast cancer treatment and prevention methods

| Adjuvant agents | Cardiovascular adverse effects | Prevention |
|-----------------|-------------------------------|------------|
| Anthracycline (e.g. doxorubicin and epirubicin) | Left ventricular dysfunction, heart failure, myocarditis, pericarditis, atrial fibrillation, ventricular tachycardia, ventricular fibrillation, and QTc prolongation (doxorubicin) | • Identification and treatment of cardiovascular risk factors  
• Limiting of cumulative dose  
• Alternative delivery systems (liposomal doxorubicin)  
• Continuous infusions  
• The use of cardioprotective drugs: Dexrazoxane, ACE-Is or ARBs, beta-blockers, statins  
• Avoiding of QT prolonging drugs and the management of electrolyte abnormalities  
• Aerobic exercise  
• Identification and treatment of cardiovascular risk factors  
• The use of ACE-Is, beta-blockers  
• Treatment of comorbidities (CAD, HF, PAD, and HTN)  
• Avoiding of QT prolonging drugs  
• Management and treatment of electrolyte abnormalities |
| HER-2-directed therapies (e.g. trastuzumab and pertuzumab) | Left ventricular dysfunction and heart failure | • Identification and treatment of cardiovascular risk factors  
• The use of ACE-Is, beta-blockers  
• Treatment of comorbidities (CAD, HF, PAD, and HTN) |
| Alkylating agents (e.g. cyclophosphamide) | Left ventricular dysfunction, heart failure, myocarditis, pericarditis, arterial thrombosis, bradycardia, atrial fibrillation, and supraventricular tachycardia | • Identification and treatment of cardiovascular risk factors  
• Treatment of comorbidities (CAD, HF, PAD, and HTN) |
| Antimetabolites (e.g. 5-fluorouracil and capecitabine) | Coronary thrombosis, coronary artery spasm, heart failure, left ventricular dysfunction, Takotsubo-like syndrome, cardiomyopathy, myocarditis, pericarditis, and arrhythmias | • Identification and treatment of cardiovascular risk factors  
• Treatment of comorbidities (CAD, HF, PAD, and HTN)  
• Avoiding of QT prolonging drugs  
• Management and treatment of electrolyte abnormalities |
| Taxanes (e.g. paclitaxel) | Left ventricular dysfunction, ventricular ectopy, and bradycardia, and heart block | • Identification and treatment of cardiovascular risk factors  
• Treatment of comorbidities (CAD, HF, PAD, and HTN)  
• Avoiding of QT prolonging drugs  
• Management and treatment of electrolyte abnormalities |
| Tyrosine kinase inhibitor | Left ventricular dysfunction and QTc prolongation | • Identification and treatment of cardiovascular risk factors  
• Treatment of comorbidities (CAD, HF, PAD, and HTN)  
• Avoiding of QT prolonging drugs  
• Management and treatment of electrolyte abnormalities |
| Radiation therapy | Coronary artery disease, cardiomyopathy, valvular disease, pericardial disease, and arrhythmias | • Minimizing of cardiac radiation: lowering the dose of radiation and reducing cardiac volume exposed  
• Use of modern techniques based on 3D treatment planning with a dose-volume histogram and virtual simulation programme |

ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CAD, coronary artery disease; HF, heart failure; HTN, hypertension; PAD, peripheral artery disease.
Table 2: Diagnostic procedures for early detection of chemotherapy-induced breast cancer cardiotoxicity according to FDA, ASE/EACVI, ASCO, ESC, ESMO recommendations\(^{11,23,24,133-135}\)

| Guidelines | Chemotherapy agents | Measurement of LVEF by echocardiography |
|------------|---------------------|----------------------------------------|
| **Baseline** | Baseline | During treatment | At the completion of therapy |
| FDA \(^{134,135}\) | Anthracycline therapy | + | For higher cumulative anthracycline doses | Not specified |
| | HER2 targeted therapy (trastuzumab) | + | Every 3 months | Every 6 months for at least 2 years following the completion of trastuzumab as a component of adjuvant therapy |
| **During treatment** | | | |
| | Anthracycline therapy | + | If the dose is >240 mg/m\(^2\) examination should be performed prior to each additional 50 mg/m\(^2\) (LVEF and GLS with troponin I) | At the completion of therapy and 6 months later (LVEF and GLS with troponin I) |
| | HER2 targeted therapy | + | Every 3 months (LVEF and GLS with troponin I) | No routine examination recommended if asymptomatic |
| | HER2 targeted therapy after anthracycline treatment | + | Every 3 months (LVEF and GLS with troponin I) | 6 months later (LVEF and GLS with troponin I) |
| **At the completion of therapy** | | + | | |
| **ASE/EACVI\(^{11}\)** | Anthracycline therapy | | | |
| | | + | | Evaluation may be considered 6 to 12 months after the completion of a treatment in patients at increased risk |
| | HER2 targeted therapy | | | |
| | | + | | |
| | | Every 3 months (LVEF and GLS) | | |
| | | At 6–12 months, 2 years post-treatment Periodically thereafter cardiac biomarkers\(^a\) [IIIB] | | |
| **ASCO\(^{133}\)** | Anthracyclines therapy | + | If the dose exceeds 240 mg/m\(^2\) in patients with high baseline risk | At the completion of therapy |
| | HER2 targeted therapy | | + | Every 3 months | At the completion of therapy |
| | HER2 targeted therapy after anthracyclines treatment | | | At the completion of therapy |
| | | + | | |
| | | After a cumulative dose of doxorubicin 250 mg/m\(^2\) | | At 6–12 months, 2 years post-treatment |
| | | With cardiac biomarkers\(^b,c\) [IIIA] | | Periodically thereafter cardiac biomarkers\(^c\) [IIIC] |
| | | After each additional 100 mg/m\(^2\) (LVEF and GLS) [IA] | | |
| | | With cardiac biomarkers\(^b\) every 3–6 weeks or before each cycle [IIIC] | | |
| **ESC\(^{23}\)** | Anthracyclines therapy | | | |
| | | + | | |
| | | After each additional 100 mg/m\(^2\) (LVEF and GLS) [IA] | | At 6–12 months, 2 years post-treatment |
| | | With cardiac biomarkers\(^b\) every 3–6 weeks or before each cycle [IIIC] | | Periodically thereafter cardiac biomarkers\(^c\) [IIIC] |
| | | | | |

AC, anthracycline; ASCO, American Society of Clinical Oncology; ASE, American Society of Echocardiography; BNP, brain natriuretic peptide; EACVI, the European Association of Cardiovascular Imaging; ESC, European Society of Cardiology; ESMO, European Society for Medical Oncology; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor type 2; NT-proBNP, N-terminal pro brain natriuretic peptide; RT, radiation therapy; trast, trastuzumab.

\(^a\)Risk factors included age \(\geq 60\), compromised cardiac function (e.g. history of myocardial infarction, moderate valvular disease, and borderline LVEF) or \(\geq 2\) cardiovascular risk factors (smoking, hypertension, diabetes mellitus, and hyperlipidaemia).\(^{136}\)

\(^b\)Cardiac biomarkers: TroponinT/I and BNP/NT-proBNP.\(^{24}\)

\(^c\)For high risk patients (with pre-existing significant CVD) and those receiving high doses of cardiotoxic chemotherapy such as anthracycline, baseline measurement of such cardiac biomarkers should be considered [III, A].\(^{24}\)
both ventricles. The measurement of myocardial deformation, especially with the use of STE method, is characterized by high repeatability of measurements and precedes the decrease in left ventricular ejection fraction during oncological treatment. The ASE/EACVI consensus defines that a relative percentage decrease of GLS by >15% from baseline is a clinically relevant evidence of subclinical left ventricular dysfunction. The disadvantage of this method involves the variability of results depending on the device, software, or patient’s age and sex. Therefore, it is recommended to evaluate GLS, preferably on the same device, by the same examiner, before the initiation of treatment, during and after the completion of treatment; subsequent measurements should be compared with baseline measurements.

Echocardiography can also be used to assess other parameters of myocardial function, which have not been included in current recommendations and which may be important in predicting the subclinical cardiotoxicity of radiotherapy and chemotherapy.

Changes in left ventricular diastolic function parameters, including mitral inflow wave velocity, E/A ratio, pulmonary vein flow, isovolumetric diastolic time, or tissue Doppler velocity, can be observed in patients undergoing oncological treatment a few hours after chemotherapy.

A significant decrease in right ventricular systolic and diastolic function and changes in the volume and function of the left atrium in treated oncological patients are also considered as an early marker of CTRCD.

Studies and results presenting promising parameters of significant importance in the assessment of oncological treatment related complications are summarized in Table 3.

Other imaging techniques

Radioisotope ventriculography (MUGA, multiple gate acquisition scan) eliminates inter-observer variation in LVEF assessment. However, it exposes patients to radiation and provides limited information on cardiac structure and diastolic function. In turn, magnetic resonance imaging of the heart allow to thoroughly estimate myocardial structures and function, which are difficult to evaluate by echocardiography, particularly in case of unsatisfactory quality of echocardiographic imaging. Moreover, it is the non-invasive tool for assessment and monitoring of cardiotoxicity, including cardiac tissue characterization, perfusion, and features, which may assist the differential diagnosis (ischaemic and non-ischaemic) and management of myocardial injury in cancer survivors. However, due to the high cost and limited availability, this imaging method is not the first-line examination used in routine monitoring of patients undergoing cardiotoxic therapy.

Biomarkers

The monitoring of myocardial function with the use of repeated echocardiographic examinations in order to detect toxic effects of adjuvant breast cancer therapy on myocardium is still a suboptimal approach. The determination of cardiomyocyte-specific plasma biomarkers has proved to be a promising complement to routine echocardiography. Plasma biomarkers, cardiac troponins and natriuretic peptides, have been evaluated in many studies for their usefulness for early detection of myocardial damage in patients without clinical symptoms. Troponin concentration shows high specificity and sensitivity for myocardial damage detection. Its measurement is minimally invasive, cheaper than imaging tests, standardized (there is no variability between observers), and shows high negative predictive value, and the result is independent of the mechanism of cardiotoxicity. Cardinale et al. proved the superior diagnostic value of cardiac troponins in patients receiving high-dose (>240 mg/m²) anthracycline chemotherapy than low-dose anthracycline therapy. The troponin levels closely correlate with the subsequent reduction of LVEF; therefore, it allows identification of patients who will require further cardiovascular monitoring or cardioprotective therapy.

In turn, the study of Rüger et al. revealed that N-terminal-pro-brain natriuretic peptide (NT-proBNP) and haemoglobin but not cardiac troponin T are strongly associated with cardiotoxic reactions. In this study, electrocardiographic, echocardiographic, and haemodynamic parameters as well as NT-proBNP and cardiac troponin T were assessed in 853 early-stage breast cancer women to establish predictors of cardiotoxic reactions while undergoing chemotherapy. Natriuretic peptides, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and their N-terminal fragments (NT-proANP, N-terminal-pro-atrial natriuretic peptide; NT-proBNP) are released by cardiomyocytes in response to volume or pressure overload and wall stretching. It results in increased glomerular filtration and the excretion of water and sodium, as well as the inhibition the activity of renin-angiotensin-aldosterone (RAA) system. Moreover, they inhibit the sympathetic nervous system and directly dilate blood vessels. Therefore, they are involved in the maintenance of homeostasis related to blood pressure and circulating blood volume. Plasma level of natriuretic peptide is an important prognostic indicator of 30 day mortality in patients with decompensated heart failure related to ischaemic and non-ischaemic causes. Moreover, in combination with cardiac troponins, they are also biomarkers of chronic and functional heart damage. Therefore, their measurement is recommended and commonly used in the diagnosis and monitoring of heart failure treatment (mainly BNP and NT-proBNP due to their longest half-life). In the largest study on the role of BNP in the detection of early...
Table 3  Echocardiographic markers of early detection of chemotherapy-induced cardiotoxicity in breast cancer\textsuperscript{136–148}

| Echocardiographic parameters                                             | Study                          | Results                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 |
|------------------------------------------------------------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Left ventricular ejection fraction assessed using three-dimensional (3D) echocardiography | Thavendiranathan et al.\textsuperscript{136} | Significantly decreased: Non-contrast 3D-EF, end-diastolic, and end-systolic volume 3D-EF is also characterized by the best intra-observer and inter-observer as well as test–retest variability A strong correlation with CMR: LVEDV in RT3D TTE ($r = 0.87$ at baseline; $r = 0.95$ at 12 months, respectively) LVEF in RT3D TTE ($r = 0.91$ at baseline; $r = 0.90$ at 12 months, respectively) A modest correlation with CMR: LVEDV in 2D TTE ($r = 0.64$ at baseline; $r = 0.69$ at 12 months, respectively) LVEF in 2D TTE ($r = 0.31$ at baseline, $r = 0.42$ at 12 months, respectively) | Non-contrast 3D-EF was the most reproducible technique for LVEF and LV volume measurement within more than 1 year of follow-up RT 3D TTE is an accurate, and reproducible alternative imaging modality for the serial monitoring of LVEF in patients with breast cancer |
| Two-dimensional speckle tracking echocardiography strain imaging of the left ventricle (2D-STE) | Lo et al.\textsuperscript{138} | Global and segmental systolic strain parameters (regional strain and strain rate) with the largest decrement in the apical segment (segments with the highest radiation dose exposure) Significantly decreased (at 6 weeks after RT in comparison with baseline): Apical peak systolic strain of $-21.21\% \pm 3.49\%$ before RT vs. $-18.69\% \pm 3.34\%$ after RT, percentage change of $11.88\%, P = 0.002$; Apical peak systolic SR of $-1.17 \pm 0.24 \text{s}$ before RT vs. $-1.04 \pm 0.19 \text{s}$ after RT, percentage change of $11.11\%, P = 0.008$ Early diastolic SR in the apical segments (apical early diastolic SR, $1.54 \pm 0.45 \text{s}$ before RT vs. $1.35 \pm 0.33 \text{s}$ after RT; percentage change of $12.34\%; P = 0.034$) | Global and segmental systolic strain parameters (regional strain and strain rate) may have a potential role in the evaluation of irradiation-related cardiotoxicity |
|                                                                        | Luo et al.\textsuperscript{139} | Total GLS and GLS were significantly decreased of the endocardium in every view in group treated epirubicin at $\geq 360 \text{mg/m}^2$; $P < 0.05$ compared with patient treated this drug in lower dose Significantly decreased (before, during, and after chemotherapy): The GLS during ($-16.5 \pm 1.9\%$) and after ($-16.0 \pm 1.6\%$, chemotherapy was significantly decreased ($P < 0.01$) compared with this before ($-18.5 \pm 1.7\%$) chemotherapy The GCS during ($-19.3 \pm 3.5\%$) and after ($-19.2 \pm 3.2\%$) chemotherapy was significantly decreased ($P < 0.01$) compared with this before ($-20.9 \pm 2.9\%$) chemotherapy The RS during ($35.3 \pm 5.2\%$) and after ($35.0 \pm 6.2\%$, chemotherapy was significantly decreased ($P < 0.01$) compared with this before ($39.2 \pm 6.4\%$, chemotherapy Left ventricular longitudinal systolic dysfunction of the endocardium was detected during an early assessment using layer-specific 2D-STE GLS assessed in 2D-STE combined with hs-cTnT can effectively and precisely detect early symptoms of anthracycline-induced cardiotoxicity |
|                                                                        | Wang et al.\textsuperscript{140} | (Continues)                                                                                                                                                                                                  |                                                                                                                                                                                                     |
### Table 3 (continued)

| Echocardiographic parameters | Study | Results | Conclusions |
|-----------------------------|-------|---------|-------------|
| No significant differences (before, during, and after chemotherapy): | | | GLS reduction is frequent in patients with active cancer, it precedes LVEF reduction and cannot be anticipated by other echocardiographic parameters |
| The LVEF: (63.8 ± 2.6%), (63.8 ± 2.8%), and (64.0 ± 3.3%), respectively (P = 0.91) | | | Early changes in GLS are good predictors of subsequent development of anthracycline-trastuzumab-induced cardiotoxicity |
| T (GLS-SD), T (GCS-SD), and T (RS-SD) (P > 0.05 in all cases) | | | |
| There were no significant differences in LVEF, T (GLS-SD), T (GCS-SD), and T (RS-SD) before, during, and after chemotherapy | | | |
| The reduction of GLS was positively associated with the increase in hs-cTnT after chemotherapy (r = 0.60, P < 0.01) | | | |
| GLS reduction is frequent in patients with active cancer, it precedes LVEF reduction and cannot be anticipated by other echocardiographic parameters | | | |
| In 64 consecutive patients, 12 (19%) had ≥10% GLS relative reduction, of which 75% had no concomitant ejection fraction reduction | | | |
| Significantly reduced (compared with baseline): LV longitudinal strain, LV circumferential strain, circumferential peak systolic SR, circumferential peak early diastolic strain, right ventricular longitudinal strain, longitudinal peak systolic strain (SP < 0.05) | | | |
| GLS at T1 (first cycle): the strongest indicator of subsequent cardiotoxicity | | | |
| [area under the curve: 0.85; cut-off value: 14.06; sensitivity: 91%; specificity: 83%; P = 0.003 (T0)] | | | |
| Early changes in GLS are good predictors of subsequent development of anthracycline-trastuzumab-induced cardiotoxicity | | | |
| | | | |
| Left ventricular diastolic dysfunction | Yaylali et al. | Significantly increased (after anthracycline therapy): LA active emptying volume and fraction (P = 0.0001 and P = 0.0001); Mitr al A velocity (0.8 ± 0.2 vs. 0.6 ± 0.2, P = 0.0001); Mitr al E-wave deceleration time (201.2 ± 35.6 vs. 163.7 ± 21.8, P = 0.0001); Mitr al Awave deceleration time (0.11 ± 0.02 vs. 0.09 ± 0.02, P = 0.0001); Mitr al E/Em ratio (8.8 ± 3.2 vs. 7.6 ± 2.6, P = 0.017); Significantly decreased (after anthracycline therapy): LA passive emptying volume and fraction (P = 0.0001 and P = 0.0001); Mitr al E/A ratio (1.0 ± 0.3 vs. 1.3 ± 0.3, P = 0.0001); Mitr al Em (0.09 ± 0.03 vs. 0.11 ± 0.03, P = 0.001); | Impaired left ventricular diastolic function could contribute to the development of atrial arrhythmias in patients with breast cancer who underwent anthracycline therapy |
| | | Regional wall motion abnormality 6.25 OR [1.03; 37.95; 95% CI]; P = 0.046 | |
| | | The assessment of segmental wall motion might be a useful tool in the early detection of myocardial dysfunction | |
| | | Significant decrease in RV systolic and diastolic function during chemotherapy can probably be considered as an early indicator of anthracycline-induced cardiotoxicity | |
| Right ventricle dysfunction | AbdarEsfahani et al. | Significantly increased: RV end-diastolic diameters and Tei index (0.31 to 0.37) (P < 0.001) | |
| | | Systolic pulmonary arterial pressure (20.63 to 22.24 mmHg, P = 0.04) | |
| | | Significantly decreased: | |

---

GLS: Global Longitudinal Strain, LVEF: Left Ventricular Ejection Fraction, hs-cTnT: High-Sensitivity Cardiac Troponin T, LV: Left Ventricular, SR: Strain Rate, LA: Left Atrium, Em: Early Diastolic Strain, E/A: Early to Late Diastolic Strain Ratio, Em: Late Diastolic Strain, RV: Right Ventricular, Tei: Tissue Doppler E/A, CI: Confidence Interval, OR: Odds Ratio.
## Table 3 (continued)

| Echocardiographic parameters | Study                          | Results                                                                 | Conclusions                                                                 |
|------------------------------|--------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| RVFAC (49.83% to 43.59%),   | Wang et al. 146                 | RV FACS and RV GLS and RV GAS at C4 and at C6 (P < 0.05)                 | Significantly decreased (in comparison with state before chemotherapy):      |
| TAPSE (18.8 to 17.7 mm)     |                                | E (57.06 to 46.59 cm/s, P < 0.001), E/A ratio (1.42 to 1.18, P < 0.001), | RV GLS at C2 (P < 0.05), RV GLS and RV GAS at C4 and at C6 (P < 0.05)        |
|                              |                                | E′ (16.73 to 12.4 cm/s, P < 0.001), E′/A′ ratio (1.21 to 0.9, P < 0.001), | RV GLS and RV GAS correlate with FAC (r = 0.37, 0.26), TAPSE (r = 0.43, 0.51), and S′ (r = 0.21, 0.36) (P < 0.01) (a high sensitivity and specificity for identifying RV-FAC decline by >5%) |
|                              |                                | S′ (12.59 to 10.57 cm/s, P < 0.001)                                       | RV GLS and RV GAS and significantly increased hs-cTnI level correlate with abnormal myocardial perfusion in 18F-FDG imaging (P < 0.05) |
|                              |                                |                                                                           | RV GLS < 18.2% enabled the diagnosis of RV impairment with a sensitivity of 92.9%, diagnostic specificity of 88.2% and an area under the curve of 0.87 |
|                              |                                |                                                                           | RV GAS <26.8% enabled the diagnosis of RV damage with a sensitivity of 94.8%, a specificity of 86.6% and area under the curve of 0.86 |

### Prolonged electromechanical delay

| Choe et al. 147                | ΔLVEMDi: 23 ms was the optimal cut-off value for TIC prediction (sensitivity: 0.85; specificity: 0.78; area under the curve [AUC]: 0.882) | ΔLVEMDi and ΔLVEMDp may serve as predictors of subclinical cardiac dysfunction in breast cancer patients receiving trastuzumab |
|                              | ΔLVEMDp: 21 ms was the optimal cut-off value for TIC prediction (sensitivity: 0.96; specificity: 0.68; AUC: 0.860) |                                                                                                                                 |

### Atrial function

| Bergamini et al. 148          | LAVI: an independent predictor of TZ-induced LV dysfunction in: | The predicted probability of developing cardiotoxicity increased progressively, in parallel with LAVI values |
|                              | • a clinical model, including age and hypertension (odds ratio per 5 mL/m² LAVI increase: 1.34, 95% confidence interval: 1.03–1.82, P = 0.03); |                                                                                                                                 |
|                              | • a haemodynamic model, including ventricular sizes and systolic blood pressure level (odds ratio per 5 mL/m² LAVI increase: 1.34, 95% confidence interval: 1.01–1.81, P = 0.04) |                                                                                                                                 |

| Yaylali et al. 143            | Significantly prolonged (after anthracycline therapy): | Left atrial electrical conduction could contribute to the development of atrial arrhythmias in patients with breast cancer after anthracycline therapy |
|                              | Left intra-atrial EMD (11.4 ± 6.0 vs. 8.1 ± 4.9, P = 0.008); |                                                                                                                                 |
|                              | Left inter-atrial EMD (19.7 ± 7.4 vs. 14.7 ± 6.5, P = 0.001); |                                                                                                                                 |

---

CMR, cardiovascular magnetic resonance imaging; EMD, electromechanical delay; GCS, global circumferential strain; GLS, global longitudinal strain; LAVI, left atrial volume index; LV, left ventricle; RT, radiotherapy; RT3D TTE, real time three-dimensional transthoracic echocardiography; RV, right ventricle; RV-FAC, right ventricle fractional area change; SR, strain rate; TAPSE, tricuspid annular plane systolic excursion; ΔLVEMDi, changes in the time intervals from QRS onset on electrocardiography to the beginning of transaortic flow on pulsed-wave Doppler echocardiography; ΔLVEMDp, changes in the time intervals from QRS onset on electrocardiography to the peak of transaortic flow on pulsed-wave Doppler echocardiography.
cardiotoxicity, Skovgaard et al. demonstrated that in a group of 333 patients with different types of cancers, undergoing potentially cardiotoxic treatment, BNP level >100 pg/mL was a marker of early heart failure (HR: 5.5; 95% CI: 1.8 to 17.2, \( P = 0.003 \)). The usefulness of BNP measurement in predicting early cardiotoxicity has also been demonstrated in meta-analysis of eight cohort studies performed by Ya-di Wang et al. The study on the role of NT-proBNP as an early marker of cardiac dysfunction after the use of high doses of chemotherapy in patients with aggressive tumours revealed that persistent elevation of plasma NT-proBNP levels was associated with the deterioration of diastolic and systolic parameters of LV function as IRT (90 ms vs. 141 ms; \( P < 0.0001 \)), DecT (162 vs. 224 ms; \( P = 0.0004 \)), and LVEF (62.8% vs. 45.6%, \( P < 0.0001 \)). However, the interpretation of cardiac troponin and natriuretic peptide levels with reference to oncological therapy-induced cardiotoxicity has some limitations. The significant limitations of those methods are the lack of final agreement regarding the cut-off values for these parameters and their levels variability depending on the presence of concomitant diseases. Moreover, increased levels of cardiac biomarkers confirm pre-existing damage to the heart muscle cell. Currently, ESC and ASE experts recommend the determination of cardiac troponin as a supplement to the LVEF assessment during routine monitoring of patients undergoing cardiotoxic therapy.

### New plasma biomarkers

Many studies evaluated the clinical utility of new plasma biomarkers, such as C-reactive protein (CRP), myeloperoxidase (MPO), galectin 3 (gal-3) (fibrosis marker), BB glycogen phosphorylase (GPBB), placental growth factor (PIGF), growth differentiation factor (GDF-15), endostatin-1, as well as circulating microRNAs in the monitoring of myocardial toxicity of adjuvant breast cancer therapy.

Putt et al. assessed the role of selected biomarkers [hsTnI, NT-proBNP, hsCRP, GDF-15, MPO, PIGF, soluble fms-like tyrosine kinase-1 (sFlt-1) and gal-3] in the prediction of early cardiotoxicity in 78 patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab, and they found a significant correlation between the analysed markers (except for NT-proBNP and gal-3) and the development of cardiotoxicity in the 3rd month of therapy. After 15 months of follow-up, elevated levels hsTnI and, to a lesser extent, GDF-15 and PIGF were observed. Finally, the authors concluded that the analysis of three of the aforementioned biomarkers (MPO, PIGF, and GDF-15) could improve the identification of patients who are at risk of cardiotoxicity. However, in this study, no such relationship was found for troponin I, NT-proBNP, or hsCRP. Ky et al. have demonstrated that MPO could be used in combination with TnI to identify patients who had a significantly higher risk of cardiotoxicity as a result of combination anthracycline therapy. Patients with MPO levels in the 90th percentile had a predicted cardiotoxicity rate of 36.1% after 15 months.

A pilot study performed by Gullo et al. assessed the role of selected biomarkers (VEGF, endothelial growth factor; PIGF, placental growth factor; MPO, myeloperoxidase, cTnI, troponin I) in the detection of early cardiotoxicity in patients with early stage of HER-2 negative breast cancer treated with bevacizumab in combination with docetaxel and cyclophosphamide as an adjunctive therapy. In their study, only elevated PIGF level at baseline correlated with a subsequent significant decrease in LVEF (especially in the third cycle of chemotherapy). The decrease in VEGF concentration after 6 months correlated with higher LVEF assessed at the same time in comparison with LVEF assessed at the beginning of the study. In turn, Onitilo et al. showed that regular monitoring of hs-CRP could be beneficial for the identification of women with early stage of breast cancer and a low risk of asymptomatic trastuzumab-induced cardiotoxicity. However, this study failed to reveal such relationship for troponin I and BNP.

Recently, more and more studies have been devoted to the assessment of microRNAs as markers of early cardiotoxicity. Small non-coding single-stranded RNAs—microRNAs (miRs)—regulate gene expression at the post-transcriptional level under both physiological and pathophysiological conditions. Therefore, they play an important role in the regeneration of various tissues and organs, including myocardium. The repair of myocardial cells involves the regulation of apoptosis, proliferation, metabolism, angiogenesis, and aging by miRs. MiR-590 promotes cardiac regeneration by activating cardiomyocyte proliferation. A set of specific miRs (miR-1, miR-133, miR-208, and miR-499) is efficient at converting cardiac fibroblasts into cardiomyocytes, while miR-34a inhibits heart regeneration via the induction of apoptosis. The change in plasma level of circulating miR, including miR-1, miR-34a, and miR-150 after the exposure to anthracyclines, occurs before myocardial cell damage. Therefore, circulating miRs may pose early markers of myocardial damage, for example, after chemotherapy or ischaemia, the detection of which is possible even before the increase in other biomarkers, such as cardiac troponins or natriuretic peptides.

New plasma biomarkers can pose a promising tool for detecting early cardiotoxicity and for the identification of patients who require increased cardiovascular monitoring or cardioprotective therapy.

Studies and results presenting new biomarkers with potential significance in the detection of early cardiotoxicity are summarized in Table 4.
Genetic polymorphisms predictors of cardiotoxicity

The aforementioned new echocardiographic parameters and plasma biomarkers are considered as useful in the detection of early cardiotoxicity. They allow the identification of patients with pre-existing myocardial damage before a decrease in LVEF or the appearance of heart failure symptoms. However, this myocardial damage has irreversibly activated compensatory mechanisms and reserves in the heart muscle, which can only be slowed down by cardioprotective therapy.

Therefore, the search for a genetic predisposition to the toxic effects of chemotherapy or resistance to the adjuvant treatment of breast cancer seems to be an important direction of current clinical research. It could help to design more individualized treatment regimens with a minimal risk of cardiotoxicity for the patient. Anthracyclines, due to their high anti-cancer efficacy, are still the basis of breast cancer treatment.\textsuperscript{5,8,133} The limitation of their use is associated with the dose-dependent cardiotoxicity, which may occur even without exceeding the total dose, but also at lower doses (150 mg/m\textsuperscript{2}) that are considered as safe.\textsuperscript{186} This suggests the existence of inter-individual differences in the pharmacogenetics of anthracycline metabolism, which may have a significant impact on the anti-tumour efficacy and toxicity of these chemotherapeutics.\textsuperscript{187}

Genes encoding proteins, which play an important role in anthracycline metabolic pathway, include, but are not limited to, genes encoding drug metabolizing enzymes and proteins involved in drug transport.\textsuperscript{188} Two types of anthracycline, efflux transporter proteins (ABC, ATP-binding cassette family) and influx transporters (SLC, solute carrier family transporter), have been identified.\textsuperscript{188} Transporters belonging to the ABC family\textsuperscript{189} are transmembrane ATP-dependent pumps present, among others, in the liver, kidneys, intestines, as well as in the heart, lungs, and reproductive organs. They regulate the distribution of endogenous metabolites and xenobiotics, including chemotherapeutics and also participate in their excretion from the body. In the heart, they participate in the protection of this organ against toxic compounds and drug-induced oxidative stress.\textsuperscript{189} Moreover, proteins belonging to the ABC family are associated with cancer cell resistance to chemotherapy (MRP1, multidrug resistance-associated protein 1).\textsuperscript{190}

Influx transporters (SLC, solute carrier family transporter) are involved in the transport of substances and xenobiotics to the cell.\textsuperscript{188} Furthermore, SLC is involved in anthracycline uptake by cancer cells and other tissues, including cardiomyocytes.\textsuperscript{188} The role of polymorphisms within genes encoding transporter proteins (ABC and SLC) in anthracycline-induced cardiotoxicity or cancer cell resistance to cancer treatment is currently the subject of numerous studies since such polymorphisms may affect the efficacy and safety of chemotherapy.\textsuperscript{191–195}

The correlation between SLC28A3 rs7853758 and rs885004 polymorphisms and anthracycline toxicity has been demonstrated in two cohort studies involving paediatric anthracycline-treated patients.\textsuperscript{191,192} However, a study of adult patients with breast cancer failed to show such a relationship in case of SLC28A3 rs7853758 polymorphism.\textsuperscript{193} In turn, in a study of patients with breast cancer,\textsuperscript{194} the presence of SLC22A16 polymorphisms was associated with lower (rs714368, rs6907567, and rs723685) or greater (rs12210538) anthracycline toxicity. In a study of adult patients treated with anthracyclines for acute myeloid leukaemia, the presence of ABCG2 rs2231142 polymorphism was associated with a higher risk of cardiotoxicity.\textsuperscript{195}

The aforementioned studies suggest that genotyping combined with clinical image analysis can help to identify patients predisposed to oncological treatment-induced cardiotoxicity. This method also enables the individualization of both the treatment plan and cardiovascular monitoring.

Clinical relevance and novelty aspects in cardiotoxicity of adjuvant breast cancer treatment breast cancer cardiotoxicity

Adjuvant therapy for breast cancer (both systemic and radiation therapy) is necessary to reduce morbidity and mortality. Unfortunately, its cardiotoxicity is a limitation of this therapy. The main reason is that its use can lead to the development of heart failure and may negatively affect quality of life and prognosis. Therefore, the knowledge of the mechanisms of toxic effects of modern oncological treatment methods and the optimization of cardiovascular risk factors is of high importance. The American (ASCO and ASE) and European (ESMO, ESC, and EACVI) experts in oncology and cardiology offer general guidelines for monitoring high risk patients for cardiotoxicity. A number of risk factors are common to both breast cancer and cardiovascular disease (CVD). The cardiac risk factors and pre-existing CVD have also an influence on cancer treatment methods.\textsuperscript{196} During breast cancer treatment, surveillance, prevention, and secondary management of cardiotoxicity are crucial. Thereafter, long-term post-treatment monitoring for late cardiotoxicity and even non-treatment-related development of CVD is essential.

Modifications of risk factors owing to blood pressure control, diabetes mellitus management, a proper lipid profile as well as a promoting a healthy diet, a healthy weight, physical activity and abstinence from tobacco, can prevent about 80% CVD.\textsuperscript{197} Risk factors for breast cancer have only been discussed more recently, but there is growing awareness that through risk factor modification, some cases of breast cancer might be prevented.\textsuperscript{198} The time when best start cardioprotection is still not clearly specified. Moreover, the use of cardiovascular drugs such as beta-blockers, angiotensin-converting-enzyme inhibitors (ACEIs), and angiotensin...
| Study         | Cancer type     | No. of patient cases | Median age (year) | Cancer therapy                                                                 | Time interval                  | New biomarkers |
|--------------|-----------------|---------------------|-------------------|---------------------------------------------------------------------------------|--------------------------------|----------------|
| Ky et al.    | Breast cancer   | 78                  | 50                | Doxorubicin and trastuzumab, Doxorubicin, taxanes, and trastuzumab              | 0, 3, 6, and 15 (months)       | NSC SC - - - NSC NSC NSC - |
| Putt et al.  | Breast cancer   | 78                  | 49                | Doxorubicin, cyclophosphamide, paclitaxel trastuzumab, and ablapatinib Trastuzumab | 0, 3, 6, 9, 12, and 15 (months)| SC SC - - - SC SC NSC - |
| Morris et al.| Breast cancer   | 95                  | 46                | Doxorubicin, cyclophosphamide, paclitaxel trastuzumab, and ablapatinib Trastuzumab | 0, 2, 6, 9, and 18 (months)    | SC - - - - - - - - |
| Onitilo et al.| Breast cancer  | 54                  | >18               | Doxorubicin, cyclophosphamide, paclitaxel trastuzumab, and ablapatinib Trastuzumab | Every 3 weeks with each cycle of treatment | SC - - - - - - - - |
| Gullo et al. | Breast cancer   | 106                 | 52                | Bevacizumab and docetaxel cyclophosphamide Anthracyclines                       | 0, 3, and 6 (months)           | - SC - - - SC SC - - - |
| Bulten et al.| Breast cancer   | 59                  | 52                | Anthracyclines                                                                  | 1 year after anthracycline treatment | - - - - - - SC - - |
| Horacek et al.| Acute leukaemia| 24                  | >18               | Anthracyclines                                                                  | 0 and 6 (months)               | - - - SC - - - - - - |
| Horacek et al.| Acute leukaemia| 47                  | >18               | Anthracyclines                                                                  | Before CT/HD-CT, after first CT with ANT, after last CT with ANT | - - - SC - - - - - - |
| Zver et al.  | Multiple myeloma| 30                  | NR                | Cyclophosphamide and melphalan                                                  | 0, 15 days, 3 months           | - - SC - - - - - - - - |
| Rigaud et al.| Breast cancer   | 56                  | 49.9 ± 3.3        | Doxorubicin                                                                      | In 4 cycles for 3 months       | - - - - - - SC miR-1 |
| Qin et al.   | Breast cancer   | 363                 | NR                | Epirubicin/ cyclophosphamide, and doxorubicin                                   | 0, 3, 6, 9, and 12 (months)    | - - - - - - SC* miR-17-5p miR-20a |

ANT, anthracyclines; CT, chemotherapy; GPBB, glycogen phosphorylase isoenzyme BB; HD-CT, high dose chemotherapy; MPO, myeloperoxidase; NR, not reported; NSC, no significant correlation with cardiotoxicity or cardiac dysfunction; PI GF, placental growth factor; SC, significant correlation with lower cardiotoxicity or cardiac dysfunction; SC*, significant correlation with cardiotoxicity or cardiac dysfunction; trast, trastuzumab; VEGF, vascular endothelial growth factor.
receptor blockers, statins, or aerobic exercise to prevent cardiotoxicity is controversial and based on a limited number of clinical trials.

In meta-analysis included randomized clinical trials of adult patients that underwent chemotherapy and neurohormonal therapies (beta-blockers, ACEIs, angiotensin receptor blockers, and mineralocorticoid receptor antagonists) observed association between treatment with cardiovascular drug and higher LVEF in follow-up among cancer patients receiving chemotherapy. In turn, the CECCY (Carvedilol Effect in Preventing Chemotherapy Induced Cardiotoxicity) trial tested the use of beta-blocker (carvedilol) versus placebo in 200 patients with breast cancer and normal LVEF receiving anthracycline 240 mg/m². Carvedilol had no impact on the incidence of early onset of LVEF reduction. Statins are another class of drugs that have been evaluated for their cardioprotective role in cancer patients exposed to cardiotoxic agents. In retrospective study of Seicean et al., women receiving uninterrupted statin therapy throughout the approximately 3 year follow-up period demonstrated significantly lower hazard ratios (HR: 0.3; 95% CI: 0.1–0.9; P = 0.03) for development of heart failure as compared with the control groups. More studies regarding the use of statins are emerging in the field of cardio-oncology.

In prospective analysis of 2973 non-metastatic breast cancer women (8.6 year median follow-up), routine exercise of ≥9 MET-hour/week was associated with a reduction in CV events [new diagnosis of coronary artery disease, valve abnormality, arrhythmia, stroke, or CVD death]. Furthermore, there are data suggesting those who start physical activity after a diagnosis of breast cancer have a lower risk of death in general. The American Heart Association (AHA) recommend physical activity as an individualized cardiac rehabilitation intervention for those most at risk of developing cardiotoxicity and the European Society for Medical Oncology (ESMO) to recommend exercise for all cancer survivors. However, further large-scale studies are needed to determine specific exercise recommendations based on population and risk stratification.

Echocardiography, electrocardiography as well as with the analysis of the concentration of cardio-specific serum biomarkers (such troponin T and NT-proBNP) are the first-line diagnostic tool for the assessment of the cardiovascular system in such patients. Elevated troponin levels predict LV dysfunction in patients receiving cancer therapy. Assessment of troponin levels may be a screening test to identify patients who require referral to cardio-oncology units and benefit from preventive strategies. The low sensitivity of left ventricular ejection fraction assessment limits its use in preventive strategy. New imaging parameter, such as GLS, is more useful echocardiographic method for the detection of early myocardial damage. Moreover, the assessment of other parameters of myocardial function, which have not been included in current recommendations such right ventricular function, changes in left ventricular diastolic function or changes in the volume and function of the left atrium may be important in predicting the subclinical cardiotoxicity of radiotherapy and chemotherapy.

The search for and the analysis of new cardio-specific biomarkers in serum, such as C-reactive protein (CRP), myeloperoxidase (MPO), BB glycogen phosphorylase (GPBB), placental growth factor (PIGF), as well as circulating microRNAs in the monitoring of myocardial toxicity of adjuvant breast cancer therapy, can pose a promising tool for detecting early cardiotoxicity and for the identification of patients who require increased cardiovascular monitoring or cardioprotective therapy. Moreover, a genetic predisposition to the toxic effects of chemotherapy or resistance to the adjuvant treatment of breast cancer seems to be an important direction of current clinical research. The genes encoding proteins, which play an important role in anthracycline metabolic pathway, in particular presented by us genes encoding proteins involved in drug transport, suggest that genotyping combined with clinical condition and imaging biomarkers may become a useful method for identifying patients at risk of developing cardiotoxicity. It could help to design more individualized treatment regimens with a minimal risk of cardiotoxicity for the patient.

**Conflict of interest**

The authors declare no conflict of interest.

**Funding**

The project is financed by Polish Mother’s Memorial Hospital Research Institute and the Polish National Agency for Academic Exchange.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019; 11: 151–164.
3. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC. Cancer
screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019; 69: 184–210.

4. Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, Lebeau A, Nyström I, Broders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Canelo-Ayar C, Warman S, Mansel R, Sardanelli F, Farmelli E, Grävingholt A, Sax-Parkinson Z. European Commission Initiative on Breast Cancer (ECIBC) Contributor Group. Breast cancer screening and diagnosis: a synopsis of the European breast guidelines. Ann Intern Med 2020; 172: 46–56.

5. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Grant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thürlimann B. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Conference: Wínters for the primary therapy of early breast cancer. Ann Oncol 2019; 30: 1541–1557.

6. Hoon Tan P, Ellis I, Allison B, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schmitt S, Sotiriou C, van Diest P, White VA, Lokuhetty D, Cree IA. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the breast. Histopathology 2020; 77: 181–185.

7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Gergenmenshchikov A, Williams C, Zhu SX, Lønning PE, Barresen-Dahl AE, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752.

8. Grudzinskas GJ, Anderson BO, Balmforth R, Blair SL, Burstein HJ, Curr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O’Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sirpati A, Smith KL, Smith ML, Soliman H, Somlo G, Telll M, Ward JH, Shead DA, Kumar R. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw 2017; 15: 433–451.

9. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 2014; 89: 1287–1306.

10. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900–2902.

11. Plana JC, Galderisi M, Baron A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebaq IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCarra JM, Edvardsen T, Flam JD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063–1093.

12. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh EH. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639–1642.

13. Blum RH, Cheson BK, Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249–259.

14. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–468.

15. Cuomo A, Rodolico A, Galdieri A, Russo M, Campi G, Franco R, Bruno D, Aran L, Carannante A, Attanasio U, Tocchetti C, Varricchi G, Mercurio V. Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients. Card Fail Rev 2019; 5: 112–118.

16. Moazed S. Anthracycline-induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient-specific care. Clin Transl Med 2017; 6: 17.

17. Canzonieri VC, Oyelere AK. Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res 2008; 36: 6825–6834.

18. Nebigil CG, Desaubry L. Updates in cardiotoxicity of old and new cardiotoxic drugs in cancer patients. Card Fail Rev 2019; 5: 112–118.

19. Pirollo A, Iskandrian AE, Ricciardi CA, Pasquale F, Dewan R, Tchervenkov CI, Sacks S, Pantoja A, Chauhan MS, Biagini F, Lyu YL, Liu LF, Yeh ETH. Identification of Tumours Ed- of old and new cardiotoxic drugs in cancer patients. Card Fail Rev 2019; 5: 112–118.

20. Artigou JY. Cardiac side-effects of cancer therapy. Int J Cardiol 2010; 144: 3–15.

21. Mehra LS, Watson KE, Baron A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuoza T, Piña IL, Volgman AS. American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018; 137: e30–e66.

22. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355–365.

23. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a re- view on pharmacology, metabolism and side effects. Eur J Drug Metab 2009; 10: 470–481.

24. Cardinale D, Colombo A, Lamantia G, Colombo N, Civeilli M, De Giacomini G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic ther- apy. J Am Coll Cardiol 2010; 55: 213–220.

25. Howe LR, Brown PH. Targeting the HER/EGF/Rerb family to prevent

ESC Heart Failure (2021) DOI: 10.1002/ehf2.13365
breast cancer. *Cancer Prev Res* 2011; 4: 1149–1157.

31. Yarden Y. The EGFR family and its ligands in human cancer. *Eur J Cancer* 2001; 37: 3–8.

32. Moasser MM. The oncogene HER2; its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene* 2007; 26: 6469–6487.

33. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist* 2009; 14: 320–368.

34. Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovasculardefinition and disease. *Circulation Research* 2012; 111(10): 1376–1385.

35. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med* 2007; 357: 39–51.

36. Ewer MS. Cardiotoxicity profile of trastuzumab. *Drug Saf* 2008; 31: 459–467.

37. Ewer MS, Voellet MH, Durand J-B, Woodlief ML, Valero V, Lessani DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol* 2005; 23: 7820–7826.

38. Slamon D, Eiermann W, Robert N, Pienaar RS, Steinmann E, Smedts F, Lluch A, Vooletich MT, Durand J-B, Ewer SM, Ewer MS. Cardiotoxicity of trastuzumab. *Ann Oncol* 2020; 31: 1623–1649.

39. Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC). *Curr Med Res Opin* 2012; 28: 1263–1279.

40. Costa RB, Kurra G, Greenberg L, Miller DL, Davis JR, Valero V, Lenihan DJ, Reversibility of trastuzumab-related cardiotoxicity. A unique clinical and pathological entity. *Lancet* 1976; 1: 58–32.

41. Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, Morioka S, Furukawa Y. Pulmonary fatal cardiotoxicity following cyclophosphamide therapy. *J Cardiol* 2009; 54: 330–334.

42. Kamezaki K, Fukuda T, Makino S, Harada M. Cyclophosphamide-induced cardiomypathy in a patient with seminoma and a history of mediastinal irradiation. *Intern Med* 2005; 44: 120–123.

43. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. *Lancet* 2000; 355: 805–806.

44. Santos GW, Sensenbrenner LL, Burke PJ, Colvin M, Owens AH Jr, Bias WB, Slavin RE. Marrow transplantation in man following cyclophosphamide. *Transplant Proc* 1971; 3: 400–404.

45. Goldberg MV, Antman EM, Guze CE, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. *Blood* 1986; 68: 1114–1118.

46. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemo-therapy for lymphoma and breast cancer: prognostic factors. *Bone Marrow Transplant* 2000; 25: 885–894.

47. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine. *Biochemistry* 1974; 13: 471–481.

48. Sommer H, Santi DV. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluorouracil-dose-chemo-therapy for lymphoma and breast cancer: prognostic factors. *Anticancer Drugs* 2001; 12: 639–646.

49. Malen-Martino M, Jolimaitre P, Martin R. The prodrugs of 5-fluorouracil. *Curr Med Chem Anticancer Agents* 2002; 2: 2153–2160.

50. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. *BMC Pharmacol Toxicol* 2014; 4: 47.

51. Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. *Curr Oncol Rep* 2016; 18: 6.

52. Jensen SA, Sorensen JB. 5-Fluorouracil-based therapy induces endothelial injury having potential significance to development of clinically overt cardiotoxicity. *Cancer Chemother Pharmacol* 2012; 69: 57–64.
65. Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B. Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis 2013; 24: 90–94.

66. Joy G, Issa H, Karoudi AR, White SK. Fluorouracil-induced Takotsubo cardiomyopathy causing cardiogenic shock: a case report of clinical and acute cardiac magnetic resonance imaging features. Eur Heart J Case Rep 2019; 3: 1–6.

67. Chong JH, Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil cardiotoxicity: reversible phenomenon observed in a patient with esophageal cancer treated with fluorouracil. J Cases 2019; 24: 257–265.

68. Babian A, Beretta G, Clerici M. Fluorouracil-induced Takotsubo cardiomyopathy: reversible mechanisms, existing management options and future directions. Interv Cardiol 2019; 14: 89–94.

69. Moriyama S, Sakelariou D, Koufos C, Stamatelos G. Cardiac exposures in breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 68: 505–510.

70. O’Leary J, Volm M, Wasserheit C, Muggia F. Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology (Williston Park) 1998; 12: 23–27.

71. Olijja I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Targets 2016; 26: 1–20.

72. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253–265.

73. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XV, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting the BCL-2 family as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 424–433.

74. Rowinsky EK, Shults AM, Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergy with trastuzumab and taxanes. Cardiov Gas Ther 2006; 318: 424–433.

75. Wöckel A, Wolters R, Wiegel T, Novopasheny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L, BREL Study Group. The impact of radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 patients. Ann Oncol 2014; 25: 628–632.

76. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2010; 61: 2319–2328.

77. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557–565.

78. Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. Int J Radiat Oncol Biol Phys 2007; 69: 1484–1495.

79. Alemán BMP, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, Vrielinc C, Darby SC. Cardiovascular disease after cancer therapy. EJC Suppl 2014; 12: 18–28.

80. Holley AK, Miao L, St. Clair DK, St. Clair WH. Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases. Antioxid Redox Signal 2014; 20: 1567–1589.

81. Sato K, Mizuno Y, Fuchikami H, Kato M, Shimo T, Kubitb J, Takeda N, Inoue Y, Seto H, Okawa T. Comparison of radiation dose to the left anterior descending artery by whole and partial breast irradiation in breast cancer patients. J Contemp Brachytherapy 2015; 7: 23–28.

82. Demirci S, Nam J, Hubbs JL, Nguyen T, Marks LB. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys 2009; 73: 980–987.

83. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart 2016; 102: 269–276.

84. Brand MD, Abadi CA, Auranen MP, Dauerman HL, Meyer TE. Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 2001; 10: 681–685.

85. Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, Vos JM, Bos WW, Biessen DH, Post MC. Assessment of valvular disorders in survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy ± chemotherapy. Am J Cardiol 2016; 117: 691–696.

86. Liu LK, Ouyang W, Zhao X, Su SF, Yang Y, Ding WJ, Luo DX, He ZX, Lu B. Pathogenesis and prevention of radiation-induced myocardial fibrosis. Asian Pac J Cancer Prev 2017; 18: 583–587.

87. Gagliardi G, Constine LS, Moiseenkov V, Correa C, Pierce LJ, Allen AM, Marks LB. Radiation-dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76: S77–S85.

88. Garibaldi C, Jereczek-Fossa BA, Marvao G, Dicuonzo S, Rojas DP, Cattani F, Starzyńska A, Ciardo D, Surgo A, Leonardi MC, Ricotti R. Recent advances in radiation oncology. Esance Mmds Med 2017; 11: 785.

89. Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res 2016; 57: 439–448.

90. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766–773.

91. Takata N, Kataoka M, Hamamoto Y, Tsurukoa S, Kanazki H, Uwatsu K, Nagasaki K, Mochizuki T. Risk factors for periendocardial effusion after chemoradiotherapy for thoracic esophageal cancer—comparison of four-field technique and traditional two opposed fields technique. J Radiat Res 2018; 59: 291–297.
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications

103. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139–3148.

104. Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol 2005; 17: 153–159.

105. Coccaro M, Gallucci G. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer. J Clin Oncol 2008; 26: 3288.

106. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993; 11: 1208–1215.

107. Eldabaje R, Le DL, Huang W, Yang LX. Radiation-associated cardiac injury. Anticancer Res 2015; 35: 2487–2492.

108. Carver JR, Szalda D, Ky B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 2013; 40: 229–238.

109. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007; 8: 1059–1058.

110. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.

111. Jay SM, Murthy AC, Hawkins JF, Wartzel JR, Steinhauser MI, Alvarez LM, Gannon J, Macrae CA, Griffith LG, Lee RT. An engineered bivalent neutregulin protects against doxorubicin-induced cardiotoxicity with reduced pronosomal potential. Circulation 2013; 128: 152–161.

112. Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE. Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes. Pediatrics 2012; 130: 1003–1011.

113. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM. Different anthracycline derivate for deriving cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 3: CD005006.

114. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011; 124: 642–650.

115. Chicco AJ, Hydock DS, Schneider CM, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol 2006; 100: 519–527.

116. Hornsby WE, Douglas PS, West MJ, Kenjale AA, Lane AR, Schwarz ER, Ray KA, Herndon JE, Coan A, Gutierrez A, Hornsby KP, Hamilton E, Wilke LG, Kimmick GG, Peppercorn JM, Jones LW. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol 2014; 53: 65–74.

117. Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res 2009; 15: 4963–4967.

118. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for patients receiving anthracyclines. Cochrane Database Syst Rev 2011; 6: CD003917.

119. Vjejponga P, Yeh ET. Topoisomerase II: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 2014; 95: 45–52.

120. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase IIβ mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67: 8839–8846.

121. Cardinale D, Colombo A, Sandri MT, Lampianti G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474–2481.

122. Nakamai H, Tsumura K, Terada Y, Akkaya H, Kaya EG, Akpek M, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 2015; 17: 81–89.

123. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demircan M, Aşag M. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2011; 58: 988–989.

124. Kaya MG, Ozguroglu I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardio-myopathy. Eur Heart J 2013; 35: 936–940.

125. Kaya MG, Ozguroglu I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 2013; 15: 2492–2498.

126. Estevé J, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 2900–2909.

127. Thakur A, Witeles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 2014; 20: 155–158.

128. Armenian SA, Lacchetti C, Barac A, Carver J, Constine LS, Dengeluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mechi J, Oefinger K, Ray K, Ruddy K, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Am Coll Cardiol 2013; 61: 2355–2362.

129. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya A, Akpek M, Kalay N, Dikilitas M, Yarlioglu M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY. Protective effects of nebulized against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013; 167: 2306–2310.

130. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013; 6: 420–426.

131. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2019; 99: 103004.

132. ESC Heart Failure (2021) DOI: 10.1002/ehf2.13365.
in patients with breast cancer after treatment with anthracyclines. *Arq Bras Cardiol* 2016; 107: 411–419.

144. Barros MVL, Macedo AVS, Sarvari SI, Faleiros MH, Felipe PT, Silva JLP, Edvardsen T. Left ventricular regional wall motion abnormality is a strong predictor of cardiotoxicity in breast cancer patients undergoing chemotherapy. *Arq Bras Cardiol* 2019; 112: 50–56.

145. Abdar Esfahani M, Mokarian F, Karimpinann M. Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy. *Postgrad Med J* 2017; 93: 271–274.

146. Wang Y, Zhang P, Liu K, Zhang J, Ma X, Li L, Li M, Liu J. Evaluation of changes in right ventricular myocardial mechanical properties in breast cancer patients receiving pirarubicin using three-dimensional speckle tracking imaging. *Nan Fang Yi Ke Da Xue Xue Bao* 2018; 38: 1032–1038.

147. Choe JC, Choi JH, Choi JH, Ahn J, Park JS, Lee HW, Oh JH, Lee HC, Cha KS, Hong TJ. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer. *ClinCardiol* 2018; 41: 1308–1314.

148. Bergamini C, Dolci G, Rossi A, Torelli F, Ghiselli L, Trevisani L, Vinco G, Truong SE, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. *Cardio Oncol Lett* 2016; 11: 3483–3492.

149. Stein BC, Levin RI. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. *Am Heart J* 1998; 135: 914–923.

150. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. *PLoS One* 2014; 9: e90736.

151. Novo G, Cadeddu C, Sucato V, Pagliaro P, Romano S, Tocchetti CG, Zito C, Longobardo L, Nodari S, Penco M. Role of biomarkers in monitoring antibiotic cardiotoxicity. Special issue on cardiotoxicity from antibiotic drugs and cardioprotection. *J Cardiovasc Med* 2016; 17: 27–34.

152. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematologic malignancies. *Ann Hematol* 2003; 82: 218–222.

153. Skovgaard D, Hasbach P, Kjær A. Biomarkers for anthracycline-induced cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. *J Clin Oncol* 2010; 38(16 suppl): 1037–1041.
Adjuvant breast cancer treatments cardio toxicity and modern methods of detection and prevention of cardiac complications

C, Fasching PA, Nekliudova V, Garfias-Macedo T, Hasenfuß G, Haverkamp W, Loibl S, von Haehling S. Cardiotoxicity and cardiovascular biomarkers in patients with breast cancer: data from the GeparOcto-BGB 84 trial. *J Am Heart Assoc* 2020; 9: e018433.

164. Luers C, Sutcliffe A, Binder L, Irle S, Pieske B. NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies. *Clin Biochem* 2013; **46**: 1013–1019.

165. Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo B, Guida V, Braga S, Pedretti RF, Lagioia R, Frigerio M, Catanzaro R, Oliva F. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. *Int J Cardioiol* 2013; **168**: 2120–2126.

166. Walker DB. Serum chemical biomarkers of cardiac injury for nonclinical safety testing. *Toxicol Pathol* 2006; 34: 94–104.

167. Gaggini HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. *Biochim Biophys Acta* 2013; **1832**: 2442–2450.

168. Ponikowski P, Voors A, Anker SD, Bueno H, Cleland JG, Coats A, Falk V, Gonzalez-Juanatey JR, Hackam D, Helgoë C, Jankowska EA. 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; 37: 2129–2200.

169. Morris PG, Chen C, Steinart G, Fleisher M, Lin N, Moy B, Come S, Cooper ME, Abbruzzese A, Lehman RP, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Tropinin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. *Clin Cancer Res* 2011; **17**: 3490–3499.

170. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. *Breast Cancer Res Treat* 2012; **134**: 291–298.

171. Gullo G, Eustace AJ, Canonici A, Collins DM, Kennedy MJ, Grogan L, Reaithai BO, McCaffrey J, Krause M, Martin MJ, Gupta B, Leonard G, O’Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernandez A, Parker I, Murray DW, O’Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O’Donovan N, Gallagher WM, Ky B, Tryfonopoulos D, Moulton B, Byrne A, Crown J. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial. *Ther Adv Med Oncol* 2011; **11**: 1–9.

172. Bulten BF, Verberne HJ, Bellersen L, Oyen WJ, Sabaré-Llobera A, Mavinkurve-Groothuis AM, Kapusta L, van Laarhoven HW, de Geus-Oei LF. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. *Chemother Pharmacol* 2015; **76**: 957–967.

173. Horacek JM, Jebavy L, Vasatova M, Pudil R, Tichy M, Jakl M, Maly J. Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia. *Bratisl Lek Listy* 2013; **114**: 90–104.

174. Horacek JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. *Exp Oncol* 2010; **32**: 217–229.

175. Zver S, Zadnik V, Čermelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Int J Hematol* 2008; **88**: 227–236.

176. Rigaud VO, Ferreira LR, Ayub-Ferreira SM, Ávila MS, Brandão SM, Cruz FD, Santos MH, Cruz CB, Alves MS, Issa VS, Guimarães GV, Cunha Neto E, Bocchi EA. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. *Oncotarget* 2017; **8**: 6994–7002.

177. Qin X, Chang F, Wang Z, Jiang W. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer. *Cancer Biomark* 2018; **23**: 473–484.

178. Koutouva L, Sterbova M, Prazourkova E, Pospisilova S, Svobodova I, Horinek A, Lysak D, Korabeczna M. The impact of standard chemotherapy on miRNA signature in plasma in AML patients. *Leuk Res* 2015; **39**: 1389–1395.

179. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takeban-Mori R, Nishi E, Hasegawa K, Kita T, Kimura T. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. *Cardiovasc Res* 2010; **87**: 656–664.

180. Ruggeri C, Giofré S, Achilli F, Colombo GI, D’Alessandra Y. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. *Heart Fail Rev* 2018; **23**: 109–122.

181. Giofré S, Ricci V, Vavassori C, Ruggeri C, Chiesa M, Alferi I, Zorzan S, Buzzetti M, Milano G, Scopea A, Castiglioni L, Sironi L, Pompilio G, Colombo GI, D’Alessandra Y. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity. *Biomed Pharmacother* 2019; **110**: 1–8.

182. Wang J, Martin JP. Macro advances in microRNAs and myocardial regeneration. *Curr Opin Cardiol* 2014; **29**: 207–213.

183. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Miroutsou M, Dzau VJ. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. *Circ Res* 2012; **110**: 1465–1473.

184. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. *Nature* 2011; **470**: 336–342.

185. Desai VG, Kwelck JC, Vijay V, Moland CL, Herman EH, Lee T, Han T, Lewis SM, Davis KJ, Muskelshilvili L, Kerr S, Fuscoe JC. Early biomarkers of doxorubicin-induced heart injury in a mouse model. *Toxicol Appl Pharmacol* 2014; **281**: 227–236.

186. Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. *J Hum Genet* 2013; **58**: 346–352.

187. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mine SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol* 2005; **23**: 2629–2636.

188. Megias-Vericat JR, Martinez-Cuadron D, Herrera MJ, Alino SF, Poveda JL, Sanz MA, Montesinos P. Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia. *Curr Drug Metab* 2018; **19**: 55–74.

189. Villanueva S, Zhang W, Zecchinati F, Mottino A, Vore M. ABC transporters in extrahepatic tissues: pharmacological regulation in heart and intestine. *Curr Med Chem* 2019; **26**: 1155–1184.

190. Tian C, Ambrosone CB, Darmy K, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Mysick K, Gallion H, DeLoia JA. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol* 2012; **124**: 575–581.

191. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM,
192. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR. CPNDS consortium validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. *Pediatr Blood Cancer* 2013; 60: 1375–1381.

193. Vulsteke C, Pleil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Diudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. *Breast Cancer Res Treat* 2015; 152: 67–76.

194. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. *Br J Cancer* 2010; 102: 1003–1009.

195. Megías-Vericat JE, Montesinos P, Herrero MJ, Moscardó F, Bosó V, Rojas I, Martínez-Cuadrón D, Hervás D, Boluda B, García-Robles A, Rodríguez-Veiga R, Martín-Cereuuela M, Cervera J, Sendra L, Sanz J, Miguel A, Lorenzo I, Poveda JL, Sanz MA, Aliño SF. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. *Leuk Lymphoma* 2017; 58: 1197–1206.

196. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. *Circulation* 2016; 133: 1104–1114.

197. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turner TN, Virani SS, Woo D, Yeh RW, Turner MB. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association. *Circulation* 2016; 133: 38–360.

198. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, García-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. *Breast Cancer Res* 2014; 16: 446.

199. Vadugananathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, Chandra A, Haykowsky M, Ky B, Mosleh J, Nohria A, Butler J, Pandey A. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. *JACC Cardiovasc Interv* 2019; 1: 54–65.

200. Avila MS, Ayub-Ferreira SM, de Barros W, Thomas RJ, Treat-Jacobson DJ, Wright JS, American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation* 2019; 139: e997–e1012.

201. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. *J Am Coll Cardiol* 2012; 60: 2384–2390.

202. Jones LW, Habel LA, Welszien E, Castillo A, Gupta D, Kroenke CH, Kwan ML, Quesenberry CP Jr, Scott J, Sternfeld B, Yu A, Kushi LH, Caan BJ. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. *J Clin Oncol* 2016; 34: 2743–2749.

203. Irwin MI, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD, Baumgartner RN, Baumgartner KB, Bernstein L. Influence of pre-and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. *J Clin Oncol* 2008; 26: 3958.

204. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, Ligibel JA, Lopez G, Madan K, Oeffinger KC, Salamone J, Scott JM, Squires RW, Thomas RJ, Treat-Jacobson DJ, Wright JS, American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation* 2019; 139: e997–e1012.

205. Mincu LR, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, Totzek M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. *Eur J Heart Fail* 2020; 22: 350–361.